Market Place
Sourcing Support
Hoth Therapeutics Reports Positive HT-VA CRADA Data
13 Apr 2026 //
PR NEWSWIRE
Hoth Therapeutics Closes $2.0M Registered Direct Offering
02 Apr 2026 //
PR NEWSWIRE
HT-001 Meets Primary Endpoint; Trial Expanded in Hungary
01 Apr 2026 //
PR NEWSWIRE
Hoth Therapeutics Gets Chinese Patent for Cancer Cell Targeting
31 Mar 2026 //
PR NEWSWIRE
Hoth Pharma Uses Openclaw AI To Speed Up Drug Discovery
26 Mar 2026 //
PR NEWSWIRE
Hoth Therapeutics Reveals Strong HT-001 Data In EGFR Therapy
24 Mar 2026 //
PR NEWSWIRE
Hoth` HT-VA Restores Cholesterol Levels In MASLD Model
10 Mar 2026 //
PR NEWSWIRE
Hoth Therapeutics Accelerates HT-001 Trial on Patient Demand
24 Feb 2026 //
PR NEWSWIRE
Hoth Gets U.S. Notice For Exon-Skipping Targeting Allergy Disease
12 Feb 2026 //
PR NEWSWIRE
Hoth Therapeutics Reports HT-VA GDNF Outperforms Semaglutide
10 Feb 2026 //
PR NEWSWIRE
Hoth Strikes Back Against Skin Toxicities But Stock Stays Frozen
22 Jan 2026 //
FIERCE BIOTECH
Hoth Therapeutics Secures Global Patent For HT-KIT Cancer Program
21 Jan 2026 //
PR NEWSWIRE
Hoth Therapeutics Advances HT-001 Oncology Trial in EU Countries
15 Jan 2026 //
PR NEWSWIRE
Hoth Therapeutics Expands Oncology Pipeline With Dual Patent
02 Jan 2026 //
PR NEWSWIRE
Hoth Therapeutics Advances Pipeline with Key Updates
04 Dec 2025 //
PR NEWSWIRE
Hoth Therapeutics Joins NVIDIA Connect Program To Enhance AI
20 Nov 2025 //
PR NEWSWIRE
Hoth Expands AI Initiative, Chooses NVIDIA AI Enterprise Platform
08 Oct 2025 //
PR NEWSWIRE
Hoth Pharma CEO To Present At Bio-Europe Conference In Vienna
07 Oct 2025 //
PR NEWSWIRE
Hoth Pharma Expands HT-001 Development with Patent Filings
24 Sep 2025 //
PR NEWSWIRE
Hoth Therapeutics Boosts Position with HT-001, HT-KIT
16 Sep 2025 //
PR NEWSWIRE
Hoth Therapeutics` Cancer Drug HT-KIT Exceeds Preclinical Goals
02 Sep 2025 //
PR NEWSWIRE
Hoth Therapeutics Signs VA Research Deal to Advance GDNF
22 Jul 2025 //
PR NEWSWIRE
Hoth, Silo Form JV to Develop VA-Licensed GDNF Obesity Therapy
25 Jun 2025 //
PR NEWSWIRE
Hoth Therapeutics Updates On Cancer Therapeutic HT-KIT Results
29 Oct 2024 //
PR NEWSWIRE
Hoth Announces it Has Completed Manufacturing of Cancer fighting HT-KIT
05 Dec 2023 //
PR NEWSWIRE
Hoth Announces Completion of Pre-IND Meeting with FDA Regarding HT-KIT
14 Nov 2023 //
PR NEWSWIRE
FDA Grants Hoth Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
02 Oct 2023 //
PR NEWSWIRE
Hoth Announces FDA Accepts Pre-IND Submission for HT-KIT for Cancer Patients
11 Sep 2023 //
PR NEWSWIRE
Hoth Announces Positive Final Results from 14-day Phase 1b Trial of BioLexa
06 Sep 2023 //
PR NEWSWIRE
